Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial - PubMed (original) (raw)

Randomized Controlled Trial

. 2020 Jun;22(6):929-937.

doi: 10.1111/dom.13978. Epub 2020 Feb 14.

Affiliations

Randomized Controlled Trial

Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial

Lawrence Blonde et al. Diabetes Obes Metab. 2020 Jun.

Abstract

Aim: To compare the effect of liraglutide or placebo added on to sodium-glucose co-transporter-2 inhibitor (SGLT2i) ± metformin on glycaemic control in patients with type 2 diabetes.

Materials and methods: Patients with type 2 diabetes on a stable SGLT2i dose ± metformin (with HbA1c 7.0%-9.5% and body mass index [BMI] ≥ 20 kg/m2 ) were randomized 2:1 to add-on liraglutide 1.8 mg/day or placebo in this parallel, double-blind, multinational trial. Primary and confirmatory secondary endpoints were changes in HbA1c and body weight from baseline to week 26, respectively. The proportions of patients achieving HbA1c (<7.0%) targets and safety events after week 26 were also assessed.

Results: Of 303 patients randomized (one in error), 280 completed treatment. Mean changes in HbA1c from baseline to week 26 with liraglutide (n = 202) and placebo (n = 100) were - 0.98% and - 0.30%, respectively (estimated treatment difference [ETD]: -0.68% [95% CI: -0.89, -0.48]; P < 0.001). Mean body weight changes from baseline were - 2.81 versus -1.99 kg, respectively (ETD: -0.82 kg [95% CI: -1.73, 0.09]; P = 0.077); 51.8% of liraglutide-treated patients achieved HbA1c < 7.0% versus 23.2% receiving placebo (odds ratio: 5.1 [95% CI: 2.67, 9.87]; P < 0.001). More patients treated with liraglutide reported ≥1 treatment-emergent adverse events (66.3%) versus placebo (47.0%).

Conclusions: Liraglutide significantly improved glycaemic control compared with placebo in patients with type 2 diabetes, insufficiently controlled with SGLT2is with/without metformin, with no unexpected safety findings.

Keywords: glucagon-like peptide-1; liraglutide; randomized trial; sodium-glucose co-transporter-2 inhibitor.

© 2020 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

PubMed Disclaimer

Conflict of interest statement

La.B. declares research support from Janssen, Lexicon, Merck, Novo Nordisk and Sanofi; speaker honoraria from Janssen, Novo Nordisk and Sanofi; consultant honoraria from AstraZeneca, Gilead, Janssen, Merck, Novo Nordisk and Sanofi. P.A.G.‐H. declares research support and honoraria from Amgen, Eli Lilly and Novo Nordisk. S.M.J. declares research support, speaker honorarium and advisory board membership from TOTALL Diabetes Hormone Institute. O.M. declares speaker's bureau honoraria and advisory board membership from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk and Sanofi; speaker's bureau honorarium from Bristol Myers Squibb. R.R. declares speaker's bureau membership from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck Sharp & Dohme, Novo Nordisk, Sanofi and Takeda; research support from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Sanofi; consulting fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Sanofi. U.F., M.S.K. and M.S.P. are employees of Novo Nordisk. Li.B. and J.N. declare no conflicts of interest.

Figures

Figure 1

Figure 1

Change from baseline in HbA1c and body weight at week 26. (A) Mean HbA1c levels over 26 weeks, (B) HbA1c treatment effect at week 26 based on the in‐trial observation period, (C) mean body weight over 26 weeks, and (D) body weight treatment effect at week 26 based on the in‐trial observation period. Estimated treatment effect was calculated using treatment policy estimands with a pattern mixture model (PMM), which were based on the in‐trial observation period, including the effect of any rescue medication, regardless of whether patients prematurely discontinued trial product. Trial product estimands calculated using mixed model of repeated measurements (MMRMs) were based on the on‐treatment without rescue medication observation period. Error bars represent the standard error. ETD, estimated treatment difference

Figure 2

Figure 2

Proportion of patients reaching HbA1c targets and composite endpoints from baseline to 26 weeks (based on the in‐trial observation period)*. (A) Patients reaching an HbA1c target of <7.0%, (B) patients reaching an HbA1c target of ≤6.5%, (C) patients reaching an HbA1c target of <7.0% without severe or blood glucose (BG)‐confirmed symptomatic hypoglycaemia or body weight gain, and (D) HbA1c reduction of ≥1.0% with body weight loss ≥3%. *Treatment policy estimand using the in‐trial observation period including the effect of any rescue medication and regardless of whether subjects prematurely discontinued trial product. Hypoglycaemia classifications: severe or BG‐confirmed symptomatic: either severe according to the American Diabetes Association (ADA) definition (requiring assistance from another person) (33) or an episode accompanied by a plasma BG value of <3.1 mmol/L (56 mg/dL), with symptoms consistent with hypoglycaemia. n, number of patients experiencing at least one event; OR, odds ratio (with 95% confidence interval); %, percentage of patients experiencing at least one event

Similar articles

Cited by

References

    1. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669‐2701. - PMC - PubMed
    1. American Diabetes Association . 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes‐2019. Diabetes Care. 2019;42:S90‐S102. - PubMed
    1. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm ‐ 2019 Executive Summary. Endocr Pract. 2019;25:69‐100. - PubMed
    1. American Diabetes Association . 6. Glycemic Targets: Standards of Medical Care in Diabetes‐2019. Diabetes Care. 2019;42:S61‐S70. - PubMed
    1. Drucker DJ. The cardiovascular biology of glucagon‐like peptide‐1. Cell Metab. 2016;24:15‐30. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources